Japan's Otsuka Pharmaceutical to buy Temasek-backed Visterra for $430m

Japan's Otsuka Pharmaceutical to buy Temasek-backed Visterra for $430m

Tokyo-based healthcare company Otsuka Pharmaceutical (Otsuka), a subsidiary of Otsuka Holdings, has announced that it has entered into a definitive merger agreement to acquire antibody developer Visterra for $430 million in cash.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter